Imunon (IMNN) Competitors

Imunon logo
$0.55 -0.01 (-2.30%)
Closing price 11/20/2026 03:57 PM Eastern
Extended Trading
$0.53 -0.02 (-3.99%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IMNN vs. CNTX, BOLT, PLUR, AKTX, and MCRB

Should you buy Imunon stock or one of its competitors? Imunon's main competitors and comparable companies include Context Therapeutics (CNTX), Bolt Biotherapeutics (BOLT), Pluri (PLUR), Akari Therapeutics (AKTX), and Seres Therapeutics (MCRB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Imunon compare to Context Therapeutics?

Imunon (NASDAQ:IMNN) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Context Therapeutics' return on equity of -96.54% beat Imunon's return on equity.

Company Net Margins Return on Equity Return on Assets
ImunonN/A -518.62% -127.14%
Context Therapeutics N/A -96.54%-83.59%

4.5% of Imunon shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 2.8% of Imunon shares are held by insiders. Comparatively, 4.8% of Context Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Imunon currently has a consensus target price of $10.00, suggesting a potential upside of 1,711.59%. Context Therapeutics has a consensus target price of $6.40, suggesting a potential upside of 3,875.16%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Context Therapeutics is more favorable than Imunon.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Imunon
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Context Therapeutics
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

Imunon has a beta of 2.1, meaning that its share price is 110% more volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Context Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImunonN/AN/A-$14.49M-$3.31N/A
Context TherapeuticsN/AN/A-$36.12M-$0.46N/A

In the previous week, Imunon had 8 more articles in the media than Context Therapeutics. MarketBeat recorded 8 mentions for Imunon and 0 mentions for Context Therapeutics. Imunon's average media sentiment score of 0.64 beat Context Therapeutics' score of 0.00 indicating that Imunon is being referred to more favorably in the media.

Company Overall Sentiment
Imunon Positive
Context Therapeutics Neutral

Summary

Context Therapeutics beats Imunon on 8 of the 12 factors compared between the two stocks.

How does Imunon compare to Bolt Biotherapeutics?

Imunon (NASDAQ:IMNN) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

Imunon has higher earnings, but lower revenue than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImunonN/AN/A-$14.49M-$3.31N/A
Bolt Biotherapeutics$7.70M1.66-$33.38M-$14.97N/A

Imunon has a beta of 2.1, meaning that its stock price is 110% more volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

In the previous week, Imunon had 3 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 8 mentions for Imunon and 5 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of 0.89 beat Imunon's score of 0.64 indicating that Bolt Biotherapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Imunon
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bolt Biotherapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Imunon currently has a consensus target price of $10.00, suggesting a potential upside of 1,711.59%. Bolt Biotherapeutics has a consensus target price of $14.50, suggesting a potential upside of 195.32%. Given Imunon's higher possible upside, analysts plainly believe Imunon is more favorable than Bolt Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Imunon
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Bolt Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

4.5% of Imunon shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 2.8% of Imunon shares are held by company insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Imunon has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Bolt Biotherapeutics' return on equity of -154.11% beat Imunon's return on equity.

Company Net Margins Return on Equity Return on Assets
ImunonN/A -518.62% -127.14%
Bolt Biotherapeutics -611.47%-154.11%-57.59%

Summary

Bolt Biotherapeutics beats Imunon on 8 of the 14 factors compared between the two stocks.

How does Imunon compare to Pluri?

Pluri (NASDAQ:PLUR) and Imunon (NASDAQ:IMNN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

16.6% of Pluri shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 43.2% of Pluri shares are held by insiders. Comparatively, 2.8% of Imunon shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Imunon had 7 more articles in the media than Pluri. MarketBeat recorded 8 mentions for Imunon and 1 mentions for Pluri. Imunon's average media sentiment score of 0.64 beat Pluri's score of 0.00 indicating that Imunon is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pluri
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Imunon
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Imunon has a consensus price target of $10.00, suggesting a potential upside of 1,711.59%. Given Imunon's stronger consensus rating and higher probable upside, analysts plainly believe Imunon is more favorable than Pluri.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pluri
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Imunon
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Pluri has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Imunon has a beta of 2.1, suggesting that its share price is 110% more volatile than the broader market.

Imunon has lower revenue, but higher earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pluri$1.02M13.25-$23.82M-$2.65N/A
ImunonN/AN/A-$14.49M-$3.31N/A

Imunon has a net margin of 0.00% compared to Pluri's net margin of -1,943.87%. Pluri's return on equity of 0.00% beat Imunon's return on equity.

Company Net Margins Return on Equity Return on Assets
Pluri-1,943.87% N/A -106.56%
Imunon N/A -518.62%-127.14%

Summary

Imunon beats Pluri on 8 of the 14 factors compared between the two stocks.

How does Imunon compare to Akari Therapeutics?

Imunon (NASDAQ:IMNN) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Imunon currently has a consensus price target of $10.00, suggesting a potential upside of 1,711.59%. Akari Therapeutics has a consensus price target of $32.33, suggesting a potential upside of 350.32%. Given Imunon's higher possible upside, analysts plainly believe Imunon is more favorable than Akari Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Imunon
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

Imunon has a beta of 2.1, suggesting that its stock price is 110% more volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Akari Therapeutics' return on equity of -149.24% beat Imunon's return on equity.

Company Net Margins Return on Equity Return on Assets
ImunonN/A -518.62% -127.14%
Akari Therapeutics N/A -149.24%-74.92%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImunonN/AN/A-$14.49M-$3.31N/A
Akari TherapeuticsN/AN/A-$17.30MN/AN/A

In the previous week, Imunon had 5 more articles in the media than Akari Therapeutics. MarketBeat recorded 8 mentions for Imunon and 3 mentions for Akari Therapeutics. Imunon's average media sentiment score of 0.64 beat Akari Therapeutics' score of 0.00 indicating that Imunon is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Imunon
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Akari Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

4.5% of Imunon shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 2.8% of Imunon shares are held by company insiders. Comparatively, 30.0% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Akari Therapeutics beats Imunon on 7 of the 12 factors compared between the two stocks.

How does Imunon compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Imunon (NASDAQ:IMNN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Seres Therapeutics has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, Imunon has a beta of 2.1, meaning that its share price is 110% more volatile than the broader market.

Seres Therapeutics has higher revenue and earnings than Imunon. Seres Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seres Therapeutics$790K16.11$5.70M-$5.00N/A
ImunonN/AN/A-$14.49M-$3.31N/A

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by insiders. Comparatively, 2.8% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Imunon has a net margin of 0.00% compared to Seres Therapeutics' net margin of -2,209.55%. Seres Therapeutics' return on equity of -194.42% beat Imunon's return on equity.

Company Net Margins Return on Equity Return on Assets
Seres Therapeutics-2,209.55% -194.42% -58.15%
Imunon N/A -518.62%-127.14%

Seres Therapeutics presently has a consensus target price of $17.00, indicating a potential upside of 1,261.09%. Imunon has a consensus target price of $10.00, indicating a potential upside of 1,711.59%. Given Imunon's higher probable upside, analysts plainly believe Imunon is more favorable than Seres Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Seres Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Imunon
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Imunon had 4 more articles in the media than Seres Therapeutics. MarketBeat recorded 8 mentions for Imunon and 4 mentions for Seres Therapeutics. Imunon's average media sentiment score of 0.64 beat Seres Therapeutics' score of -1.00 indicating that Imunon is being referred to more favorably in the news media.

Company Overall Sentiment
Seres Therapeutics Negative
Imunon Positive

Summary

Seres Therapeutics beats Imunon on 8 of the 14 factors compared between the two stocks.

Get Imunon News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMNN vs. The Competition

MetricImunonBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.47M$3.93B$7.43B$10.86B
Dividend YieldN/A3.79%2.51%4.74%
P/E RatioN/A24.5831.2925.82
Price / SalesN/A15.328.115.44
Price / CashN/A21.9220.2520.77
Price / Book-4.604.124.343.51
Net Income-$14.49M-$24.08M$3.51B$394.12M
1 Month Performance-53.61%-13.58%-10.59%-12.04%
1 Year Performance-84.84%-7.97%-4.80%-11.42%

Imunon Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMNN
Imunon
2.129 of 5 stars
$0.55
-2.3%
$10.00
+1,711.6%
-85.0%$3.47MN/AN/A20
CNTX
Context Therapeutics
2.0084 of 5 stars
$0.17
+3.1%
$6.40
+3,642.7%
-85.9%$15.24MN/AN/A15
BOLT
Bolt Biotherapeutics
3.2342 of 5 stars
$5.65
-2.6%
$14.50
+156.6%
+2.3%$15.12M$7.70MN/A23
PLUR
Pluri
0.672 of 5 stars
$0.98
-5.8%
N/A-75.9%$14.95M$1.02MN/A92
AKTX
Akari Therapeutics
2.1449 of 5 stars
$5.70
-12.4%
$32.33
+467.3%
-61.2%$14.88MN/AN/A6

Related Companies and Tools


This page (NASDAQ:IMNN) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners